[Federal Register Volume 84, Number 169 (Friday, August 30, 2019)] [Notices] [Page 45769] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2019-18730] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2017-D-2991] Pediatric Rare Diseases--A Collaborative Approach for Drug Development Using Gaucher Disease as a Model; Draft Guidance for Industry; Availability; Correction AGENCY: Food and Drug Administration, HHS. ACTION: Notice; correction. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration is correcting a notice entitled ``Pediatric Rare Diseases--A Collaborative Approach for Drug Development Using Gaucher Disease as a Model; Draft Guidance for Industry; Availability'' that appeared in the Federal Register of December 7, 2017. The document announced the availability of a draft guidance focusing on drug development for pediatric patients with Gaucher disease. The document was published with the incorrect docket number. This document corrects that error. FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993-0002, 301-796-9115. SUPPLEMENTARY INFORMATION: In the Federal Register of Thursday, December 7, 2017 (82 FR 57759), in FR Doc. 2017-26357, the following correction is made: On page 57759, in the first column, in the document heading and in the third column under Instructions, the docket number ``FDA-2017-N- 6476'' is corrected to read ``FDA-2017-D-2991''. Dated: August 26, 2019. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2019-18730 Filed 8-29-19; 8:45 am] BILLING CODE 4164-01-P